Interactions between cationic liposomes and drugs or biomolecules. Anais da Academia Brasileira de Ciências 72: 39-43 (original) (raw)
Related papers
Interactions between cationic liposomes and drugs or biomolecules
Anais da Academia Brasileira de Ciências, 2000
Multiple uses for synthetic cationic liposomes composed of dioctadecyldimethylammonium bromide (DODAB) bilayer vesicles are presented. Drugs or biomolecules can be solubilized or incorporated in the cationic bilayers. The cationic liposomes themselves can act as antimicrobial agents causing death of bacteria and fungi at concentrations that barely affect mammalian cells in culture. Silica particles or polystyrene microspheres can be functionalized by coverage with DODAB bilayers or phospholipid monolayers. Negatively charged antigenic proteins can be carried by the cationic liposomes which generate a remarkable immunoadjuvant action. Nucleotides or DNA can be physically adsorbed to the cationic liposomes to be transferred to mammalian cells for gene therapy. An overview of the interactions between DODAB vesicles and some biomolecules or drugs clearly points out their versatility for useful applications in a near future.
Cationic Liposomes as Antimicrobial Agents
This document contains a mini-review of research work on bilayer-forming cationic lipids which selfassemble in water medium as closed bilayer membranes or liposomes and behave as very potent antimicrobial agents. In contrast to conventional liposomes, the large but differential cytotoxicity of cationic liposomes has been advantageously used against pathological microrganisms. This action has been described both in vitro against Gram-negative or positive bacterial strains and in vivo, against fungus. In certain instances, synergistic drug action against yeasts for fungicidal drugs carried by the antimicrobial bilayers has been described. Given the inexpensive character of certain synthetic cationic lipids and the multiple utility of liposomal models in drug delivery, many pharmaceutical applications are to be anticipated for this convenient joint venture.
Lipid-based Biomimetics in Drug and Vaccine Delivery
InTech eBooks, 2010
Lipids provide adequate matrixes for supporting important biomolecules (proteins, DNA, oligonucleotides and polysaccharides) on model surfaces (latex, silica, silicon wafers, selfassembled monolayers, metals, polymers, insoluble drugs, biological cells and viruses). For example, biomolecular recognition between receptor and ligand can be isolated and reconstituted by means of receptor immobilization into supported lipidic bilayers on silica. This is an overview on novel lipid-based assemblies for drug and vaccine delivery. Especial emphasis will be on assemblies produced from the cationic, synthetic and unexpensive lipid dioctadecyldimethylammonium bromide (DODAB). DODAB vesicles interacted with negatively charged prokaryotic or eukaryotic cells with high affinity changing the cell surface charge from negative to positive and reducing cell viability. DODAB effects on cell viability (bacteria, fungus and cultured mammalian cells) revealed its high antimicrobial activity and differential cytotoxicity in vitro. DODAB bilayer fragments were combined with drugs, biomolecules or particles producing novel lipid-based biomimetics to deliver difficult drugs or design vaccines. Hydrophobic drug granules or aggregated recombinant antigens became well dispersed in water solution via lipid adsorption on drug particles as nanocapsules or protein adsorption onto supported DODAB bilayers. In other instances, hydrophobic drug molecules were attached as monomers to borders of lipid bilayer fragments yielding drug formulations effective in vivo at low drug-to-lipid-molar ratio. Cationic biomimetic particles from silica or latex covered with one cationic lipid bilayer proved effective for adsorption, presentation and targeting of biomolecules in vivo. Thereby antigens were effectively presented to the immune system by particles at defined and controllable sizes. The problem of delivering drugs, antigens or biomolecules to their targets in vivo is central and multidisciplinary and biomimetic assemblies are a major asset to improved and less toxic drug and vaccine delivery. Liposomes were first produced in 1965 by Alec Bangham in Cambridge UK and looked like myelin figures forming coherent and closed concentric spheroidal bilayers. From these early days up to the present, the development and diversification of the liposome "membrane" 25 www.intechopen.com
Asian Journal of Pharmaceutical Research and Development
Liposomes are sphere-shaped vesicles made up of one or more bilayers of phospholipids. The ability of delayed vesicles to transport medications, vaccines, diagnostic specialists, and other bioactive operators has accelerated development in the liposomal drug delivery system. The liposomal delivery system's pharmacyelements and pharmacokinetics properties have been altered, resulting in a higher therapeutic index and lower overall toxicity. There are many factors to consider, including size, size distribution, surface electrical potential, lamella count, and encapsulation efficacy. The use of surface modification in the development of liposomes with various mechanisms, kinetic properties, and biodistribution was discovered to be beneficial. Drug delivery, drug targeting, controlled release, and improved solubility have all been studied extensively with liposomes.
Liposomes as Drug Carrier for Novel Drug Delivery System
2018
A liposome is a tiny bubble (vesicle), made out ofthe same material as a cell membrane. Liposomes can be filled with drugs, and used to deliver drugs for cancer and other diseases. An artificial microscopic vesicle consisting of an aqueous core enclosed in one or more phospholipid layers, used to convey vaccines, drugs, enzymes, or other substances to target cells or organs. Liposomes characterize an advanced technology to deliver active molecules to the site of action, and at present, several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to 'second-generation liposomes', in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. This review discusses the classification, formulation, characterization and potential applications of liposomes in drug delivery.
A Review On Liposomes As Drug Delivery System
International Journal in Pharmaceutical Sciences, 2023
Liposomes are composed of phospholipids and lipids, forming spherical or multilayered vesicles with a lipid bilayer structure in aqueous solutions due to self-assembly of diacyl chain phospholipids. The number of bilayers and the size of vesicles influence the amount of drug encapsulation in liposomes, a crucial factor in determining their circulation half-life. This method involves coating a medication and a lipid onto a soluble carrier to create a pro-liposome, which is free-flowing and granular. When hydrated, it forms an isotonic liposomal solution. This pro-liposome approach serves as a motivation for large-scale production of liposomes containing lipophilic medications at a low cost. These systems have unique properties, including increased drug solubility (as seen with amphotericin B), protection of molecules like DNA and RNA, enhanced intracellular uptake (especially for anticancer drugs), acting as a drug depot, and enhancing drug stability. Liposomes have been successfully utilized for the delivery of various drug categories such as anti-viral, anti-cancer, anti-inflammatory, antibiotics, and anti-fungal agents. Additionally, there have been efforts in the development and characterization of liposomal drug delivery systems, for instance, liposomes containing brimonidine tartrate for ocular applications. These advancements signify the transition of liposomes from a clinically established drug delivery system to a versatile nanoparticle platform for theragnostic
Trends and developments in liposome drug delivery systems
Journal of pharmaceutical sciences, 2001
Since the discovery of liposomes or lipid vesicles derived from self-forming enclosed lipid bilayers upon hydration, liposome drug delivery systems have played a signi®cant role in formulation of potent drugs to improve therapeutics. Currently, most of these liposome formulations are designed to reduce toxicity and to some extent increase accumulation at the target site(s) in a number of clinical applications. The current pharmaceutical preparations of liposome-based therapeutics stem from our understanding of lipid±drug interactions and liposome disposition mechanisms including the inhibition of rapid clearance of liposomes by controlling size, charge, and surface hydration. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes targeted to tissues and cells with or without expression of target recognition molecules on liposome membranes. Enhanced safety and heightened ef®cacy have been achieved for a wide range of drug classes, including antitumor agents, antivirals, antifungals, antimicrobials, vaccines, and gene therapeutics. Additional re®nements of biomembrane sensors and liposome delivery systems that are effective in the presence of other membrane-bound proteins in vivo may permit selective delivery of therapeutic compounds to selected intracellular target areas. ß
Liposomes as a Novel Drug Delivery System
International Journal of Advanced Research in Science, Communication and Technology
Liposomes and liposome-derived nanovesicles including archaeosomes and virosomes have turn out to be essential service structures in vaccine improvement and the hobby for liposome-primarily primarily based totally absolutely sincerely vaccines has markedly increased. A key gain of liposomes, archaeosomes and virosomes. In general, and liposome-primarily based totally sincerely vaccine transport structures in particular, is their versatility and plasticity. Liposome composition and training may be selected to attain preferred capabilities including choice of lipid, charge, length, length distribution, entrapment and region of antigens or adjuvants. Depending on the chemical properties, water- soluble antigens (proteins, peptides, nucleic acids, carbohydrates, haptens) are entrapped withinside the aqueous inner region of liposomes, at the equal time as lipophilic compounds (lipopeptides, antigens, adjuvants, linker molecules) are intercalated into the lipid bilayer and antigens or adj...
Open Journal of Pharmacology and Pharmacotherapeutics, 2018
Liposomes, sphere-shaped vesicles consisting of one or more phospholipid bilayers, were fi rst described in the mid-60s. Nowadays, they are a very useful reproduction, reagent, and device in various scientifi c disciplines, including medicine, chemistry, biochemistry, colloid science, biology, physics, biophysics, mathematics and theoretical. After the initial discoveries liposomes have made their way to the market. Among numerous brilliant new drug delivery systems developed, liposomes characterize an advanced technology to deliver active molecules to the site of action, and at present, several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to 'second-generation liposomes', in which long-circulating liposomes are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposomes with modifi ed surfaces have also been developed using several molecules, such as glycolipids or sialic acid. This paper mini review summarizes exclusively Nano-lipids, its applications in medicine scalable techniques in treating dreadful diseases cancer, AIDS, paralysis etcand focuses on strengths, respectively, limitations in respect to industrial applicability and regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.